# Polaryx Therapeutics, Inc.: filings

PLYX · Nasdaq · CIK 2075320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/plyx.md) · [Financials](/companies/plyx/financials.md) · [Filings](/companies/plyx/filings.md) · [Insiders](/companies/plyx/insiders.md)

## Reports and events: 13 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (3 7, 8-K 5, 10-Q 2, 4 2, C-U 2, S-1/A 2, 10-K 1, 424B4 1, 8-A12B 1, ARS 1, C 1, C/A 1, CERT 1, DEF 14A 1, DEFA14A 1, DRS 1, DRS/A 1, EFFECT 1, S-1 1, S-8 1, SCHEDULE 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 19:59 ET | [8-K](/filings/0001213900-26-099416.md) | 5.07 Shareholder vote results | 0001213900-26-099416 |
| 2026-09-01 | 16:30 ET | [8-K](/filings/0001213900-26-096235.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-096235 |
| 2026-08-13 | 16:15 ET | [10-Q](/filings/0001213900-26-089118.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089118 |
| 2026-07-28 | 17:00 ET | [DEF 14A](/filings/0001213900-26-082339.md) | Proxy statement, period 2026-09-10 | 0001213900-26-082339 |
| 2026-07-21 | 16:30 ET | [8-K](/filings/0001213900-26-080041.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-080041 |
| 2026-07-17 | 08:00 ET | [8-K](/filings/0001213900-26-078912.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001213900-26-078912 |
| 2026-05-28 | 16:31 ET | [8-K](/filings/0001213900-26-062155.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-062155 |
| 2026-05-15 | 20:01 ET | [10-Q](/filings/0001213900-26-056973.md) | Quarterly report, period 2026-03-31 | 0001213900-26-056973 |
| 2026-03-24 | 17:48 ET | [10-K](/filings/0001213900-26-033064.md) | Annual report, period 2025-12-31 | 0001213900-26-033064 |
| 2026-02-05 | 16:05 ET | [SCHEDULE 13D](/filings/0001213900-26-012759.md) | Ownership report, active investor | 0001213900-26-012759 |
| 2026-01-27 | 08:02 ET | [S-1/A](/filings/0001213900-26-007973.md) | Registration statement, amended | 0001213900-26-007973 |
| 2026-01-14 | 19:30 ET | [S-1/A](/filings/0001213900-26-004079.md) | Registration statement, amended | 0001213900-26-004079 |
| 2025-11-21 | 19:16 ET | [S-1](/filings/0001213900-25-113249.md) | Registration statement | 0001213900-25-113249 |

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. No prices; not investment advice.